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Abstract
Background: This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary
efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with
relapsed / refractory lymphoma or advanced solid organ cancers and to assess HR23B protein expression by
immunohistochemistry as a biomarker of HDAC inhibitor sensitivity.
Methods: Patients with advanced solid-organ cancers with high HR23B expression or lymphomas received CXD101
at the recommended phase 2 dose (RP2D). Key exclusions: corrected QT > 450 ms, neutrophils < 1.5 × 109/L,
platelets < 75 × 109/L, ECOG > 1. Baseline HR23B expression was assessed by immunohistochemistry.
Results: Fifty-one patients enrolled between March 2014 and September 2019, 47 received CXD101 (19 solid-organ
cancer, 28 lymphoma). Thirty-four patients received ≥80% RP2D. Baseline characteristics: median age 57.4 years,
median prior lines 3, male sex 57%. The most common grade 3–4 adverse events were neutropenia (32%),
thrombocytopenia (17%), anaemia (13%), and fatigue (9%) with no deaths on CXD101. No responses were seen in
solid-organ cancers, with disease stabilisation in 36% or patients; the overall response rate in lymphoma was 17%
with disease stabilisation in 52% of patients. Median progression-free survival was 1.2 months (95% confidence
interval (CI) 1.2–5.4) in solid-organ cancers and 2.6 months (95%CI 1.2–5.6) in lymphomas. HR23B status did not
predict response.
Conclusions: CXD101 showed acceptable tolerability with efficacy seen in Hodgkin lymphoma, T-cell lymphoma
and follicular lymphoma. Further studies assessing combination approaches are warranted.
Trial registration: ClinicalTrials.gov identifier NCT01977638. Registered 07 November 2013.
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Background
Epigenetic abnormalities are important in the pathogen-
esis of many cancers, amongst which histone modifica-
tions and associated changes in chromatin structure are
some of the best described [1].
Histone de-acetylation is associated with a more closed
chromatin configuration and silencing of tumour sup-
pressor genes [2]. Currently licensed histone de-
acetylase (HDAC) inhibitors are either non-selective
across the four described classes of HDAC enzymes or
have some bias for class 1 HDACs [3]. HDACs have also
been described to have non-histone targets, for example
deacetylation of the tumour suppressor p53 increases its
activity, and other targets include heat shock protein 90
(HSP90) and nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) [4, 5].
HDAC inhibitors have been studied across numerous
cancer types and have gained regulatory approval in the
United States in relapsed / refractory (R/R) cutaneous-
and peripheral- T-cell lymphoma and in combination
with proteasome inhibitors in myeloma. Overall re-
sponse rates (ORRs) were 25–34% as single agent in T-
cell lymphoma and 34.5% in combination with Bortezo-
mib in myeloma [6], although single agent activity in
myeloma was limited [7]. The pivotal Phase 2 studies of
Romidepsin [8] and Belinostat [9] demonstrated a small
number of patients with peripheral T-cell lymphoma
had remarkably durable responses, but there are as yet
no established biomarkers to predict response to HDAC
inhibitors and potentially guide therapy [5]. Efficacy of
HDAC inhibitors as monotherapy in solid organ malig-
nancies has been limited [10, 11]. There are, however,
numerous ongoing studies evaluating HDAC inhibitors
in combination with other agents [5].
The HDAC inhibitors are generally well tolerated as
monotherapy with the most common reported adverse
events of grade 3 or more being thrombocytopenia, neu-
tropenia, gastrointestinal symptoms and fatigue [8, 12,
13]. Electrocardiogram (ECG) QTc interval prolongation
has been reported with HDAC inhibitors, warranting
particular attention during safety assessment.
CXD101
CXD101 is an investigational class 1-selective HDAC in-
hibitor. Following in vitro work demonstrating efficacy
in colon, lung, non-Hodgkin lymphoma and myeloma
cell lines, the Phase 1 dose escalation portion of this
study established a recommended Phase 2 dose (RP2D)
of 20 mg twice daily for 5 days of a 21-day cycle. Unlike
the only approved HDAC inhibitor with class 1 selectiv-
ity, romidepsin, CXD101 has no class 2 activity and im-
portantly is orally bioavailable [14, 15]. In contrast to the
experimental HDAC inhibitor entinostat, which is orally
bioavailable but inhibits both class 1 and class 4 HDACs,
the half-life of CXD101 is considerably shorter (5–12 h)
compared to 33–150 h) [16], reducing potential issues
with accumulation and prolonged washout periods. It is
hypothesised that in view of the tissue specificity of class
2 HDACs for the heart, smooth muscle, brain, liver and
colon, that CXD101 may have reduced cardiac toxicity
whilst preserving anti-tumour efficacy.
HR23B
HR23B protein, also known as UV excision repair pro-
tein RAD23 homolog B, shuttles ubiquitinated cargo
proteins to the proteasome and participates in nucleo-
tide excision repair. A genome wide loss of function
screen identified HR23B expression as a determinant of
sensitivity to HDAC inhibitor induced apoptosis in an
osteosarcoma cell line, and it is therefore a potential bio-
marker of HDAC inhibitor sensitivity [17]. The same au-
thors demonstrated that reducing HR23B expression
in vitro by short interfering RNA re-instated proteasome
activity which had been suppressed in HDAC inhibitor
treated cells, suggesting that HDAC inhibitors’ effect on
the proteasome is mediated by HR23B. Immunohisto-
chemical expression of HR23B has been reported to cor-
relate with responses to HDAC inhibitors in cutaneous
T-cell lymphoma, with high HR23B expression having a
positive predictive value of 71.7% for clinical benefit
(partial response or stable disease) [18]. A similar rela-
tionship between HR23B expression and response to
HDAC inhibitors has been seen in hepatocellular carcin-
oma with higher levels of expression associated with
higher rates of disease stabilisation [19].
Here we present final results of the Phase 2a expansion
study evaluating the safety and efficacy CXD101 in lymph-
omas and advanced solid-organ malignancies expressing
high levels of HR23B. We also assessed HR23B expression
as a biomarker of response to HDAC inhibitors.
Methods
Study design
Detailed methods of the escalation portion of the study
have been previously presented [20]. The trial was con-
ducted at the Churchill Hospital, Oxford, United King-
dom. In brief, the study employed a single-arm 3 + 3
dose escalation to identify a maximum tolerated dose of
CXD101, the highest dose at which fewer than 33% of
patients experienced a pre-defined dose limiting toxicity.
Patients were evaluated for safety on days 1, 2, 5 and 8
of cycles 1 and 2 and days 1 and a second time point of
day 8–15 in subsequent cycles. Patients received
CXD101 twice daily for days 1–5 of 21-day cycles until
disease progression, unacceptable toxicity or withdrawal
of consent. The primary end point of the expansion
component of the study was assessment of the safety
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and toxicity of the RP2D. Pharmacokinetic data were
collected and have been presented previously [20].
Eligibility
Key inclusion criteria were: age > 18 years; with a meas-
urable advanced malignant tumour [criteria of Cheson
et al 2014] [21] for patients with lymphoma and Re-
sponse Evaluation Criteria In Solid Tumors [RECIST;
version 1.1] [22] for patients with solid organ malignan-
cies; prior standard therapy; Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0 to 1; a life
expectancy of ≥12 weeks; toxicity of previous treatment
resolved to at least grade 1); adequate bone marrow,
liver and renal function as defined by absolute neutro-
phil count ≥1.5 × 109/L; platelets ≥75 × 109/L; creatinine
and bilirubin ≤1.5 x upper limit of normal; alanine ami-
notransferase or aspartate transaminase and alkaline
phosphatase ≤2.5 x upper limit of normal.
In the expansion cohort patients with solid-organ can-
cers only were required to have high tumour expression
of the HR23B by immunohistochemistry (IHC). This de-
cision was taken in view of the lack of responses in unse-
lected solid-organ cancer patients in the dose escalation
cohort and emerging similar findings with other HDAC
inhibitors. In contrast, responses were seen in patients
with lymphoma, including those negative for HR23B and
therefore this criterion was not applied to patients with
lymphoma. Patients were excluded for: previous receipt
of HDAC inhibitor; anticancer therapy within 28 days;
mean corrected QT (QTc) > 450 milliseconds; positive
serology for hepatitis B virus, hepatitis C virus or HIV;
pregnancy or breast feeding; unwillingness to use contra-
ception during and for 16 weeks after treatment with
CXD101. Echocardiograms were not required at base-
line. Staging was based on examination and computed
tomography scan of the neck, chest, abdomen, and pelvis
with unilateral bone marrow biopsy as indicated.
Toxicity
Adverse events were categorised and graded according
to the National Comprehensive Cancer Network Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 4.03. Patients were assessed during screening
and on cycle 2 day 15 by slit lamp and fundoscopy as-
sessment. Triplicate electrocardiograms (ECGs) were
performed at screening and all safety visits. Dosing was
interrupted for development of QTc > 470 milliseconds
until resolution to < 450 milliseconds and discontinued
if QTc was increased by ≥60 milliseconds or to > 500
milliseconds. AEs are presented according to number
and percentage of patients by worst grade experienced,
and by the number and percentage of administered cy-
cles affected to give an indication of the longitudinal
persistence of toxicity over time and to facilitate
comparison with published data from the escalation por-
tion of the study [20, 23].
Response evaluation
An important secondary end point of the study was pre-
liminary assessment of the efficacy of CXD101 as mono-
therapy by ORR, defined as the rate of partial response
(PR) or complete response (CR) as assessed in solid-
organ cancers by RECIST v1.1 [22], and in lymphomas
by the criteria of Cheson et al. [21]. ,Radiological assess-
ment was by computed tomography performed at base-
line and then every 2 treatment cycles. Patients without
a progression event were censored at the time of their
last assessment.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was stained
automatically with a BOND-MAX autostainer (Leica
Microsystems Inc., Buffalo Grove, Illinois), using a com-
mercial mouse monoclonal anti-HR23B antibody (BD.
Transduction Laboratories, Franklin Lakes, New Jersey).
Two independent histopathologists blinded to patient out-
come evaluated HR23B immunoreactivity in each sample
compared to control colorectal carcinoma specimens of
each intensity level. Scores were for combined nuclear and
cytoplasmic expression (1 indicates < 5%, 2 indicates 25–
50%, 3 indicates 50–75% and 4 indicates > 75%); and in-
tensity (0 indicates negative, 1 indicates weak, 2 indicates
moderate, and 3 indicates strong).
Within the expansion cohort, patients with solid-organ
tumours were eligible according to positive expression
(6–7 of 7 was considered positive). Archival or recent
formalin-fixed, paraffin-embedded tissue was used when
available.
Statistical analysis
The data are presented descriptively as absolute values
with percentages where relevant. Progression-free sur-
vival (PFS) was defined from the date of cycle 1 day 1 to
progression or death and estimated using the method of
Kaplan and Meier [24]. Median progression-free survival
is presented with 95% confidence intervals (CI). Survival
analyses were performed with Stata version 16.1 (Stata
Corp., College Station, TX, USA).
Results
Baseline characteristics
A total of 51 patients were enrolled between 12 March
2014 and 05 September 2019. Four patients did not re-
ceive CXD101 because of deterioration in laboratory pa-
rameters causing them to be ineligible by the planned
cycle 1 day 1. Thirty patients were treated in the escal-
ation phase and 17 in the expansion phase. Data were
censored 31 December 2020. Baseline characteristics of
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the 19 solid-organ cancer and 28 lymphoma patients
treated are shown in Table 1. The whole population me-
dian age was 57.4 years (range 21.7–79.4), most of the
cohort had received significant prior treatment (median
3 lines, range 0–10). Baseline tumour samples were
available for 41 patients; HR23B expression by IHC was
positive in 32 patients and negative 11 patients.
Safety
Details of the 3 + 3 dose escalation phase leading to a
recommended phase 2 dose (RP2D) of 20 mg twice a
day for 5 days of a 21-day cycle have been described else-
where [20]. Neutropenia was the dose limiting toxicity.
CXD101 was typically well tolerated. Details of treat-
ment emergent adverse events (AE) s occurring in
greater than or equal to 5% of patients are given in
Table 2. A complete table of treatment emergent AEs is
given in Supplementary Table 1. There were no deaths
related to CXD101. 29 (60%) patients experienced grade
3–4 AEs, leading to a total of 19 admissions affecting 13
(28%) of the patients, 7 of these AEs (37%) were judged
to be at least possibly related to CXD101. Grade 3–4
AEs leading to admission affected 17 (9%) of cycles. The
majority of admissions (68%) related to infections. The
most common grade 3–4 events were: neutropenia (15,
32%), thrombocytopenia (8, 17%), anaemia (6, 13%) and
fatigue (4, 9%). Grade 3 or greater neutropenia was seen
in 14% of cycles. Five episodes of febrile neutropenia oc-
curred (3% of cycles), affecting a total of 4 (8.5%) of pa-
tients. Grade 3 or 4 infection was reported in 6 (13%)
patients and occurred in 4% of cycles. Two (4%) patients
had grade 3 or 4 QTc interval prolongation; one of these
patients had a 12 year history of hypertension but nei-
ther had known cardiac disease. The most common
grade 1–2 AEs were nausea 24 (51%), anaemia 21 (45%),
fatigue 22 (47%), and vomiting 14 (30%) Any grade of
Table 1 Baseline characteristics
Characteristic Solid tumour N = 19 Haematological malignancy N = 28 Combined N = 47
Sex
Male 9 18 27
Female 10 10 20
Median age (range), years 59.2 (39.4–70.8) 49.0 (21.7–79.4) 53.1 (21.7–79.4)
Median no. of prior lines of systemic therapy (range) 2 (0–8) 4 (1–10) 3 (0–10)
ECOG performance status
0 7 10 17
1 12 18 30
Histology Colorectal 4 cHL 15
Lung 4 DLBCL 3
Upper GI 3 AITL 4
Cervix 2 PTCLNOS 2
Endometrial 1 Indolent B-cell NHL 3
Breast 1 GZL 1
Peritoneal 1
Neuroendocrine 1
Head and neck SCC 1
Meningioma 1
Stage
III 0 4 N/A
III or IIIS 2 6
IV 17 18
Baseline HR23B status (IHC)
Positive (6–7) 15 17 32
Negative (0–5) 2 9 11
Not available 2 2 4
GI gastrointestinal, ECOG Eastern Cooperative Oncology Group, cHL classic Hodgkin lymphoma, AITL angio-immunoblastic T-cell lymphoma, DLBCL diffuse large B-
cell lymphoma, GZL grey zone lymphoma, HR23B UV excision repair protein RAD23, IHC immunohistochemistry, NHL non-Hodgkin lymphoma, PTCLNOS Peripheral
T-cell lymphoma not otherwise specified
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Table 2 Treatment emergent adverse events occurring in ≥5% of patients















Blood and lymphatic system
Anaemia 21 45% 15 32% 38 20% 6 13% 11 6%
Febrile Neutropenia 4 9% 0 0% 0 0% 4 9% 5 3%
Gastrointestinal disorders
Abdominal Pain 10 21% 10 21% 15 8% 0 0% 0 0%
Diarrhoea 10 21% 8 17% 21 11% 2 4% 2 1%
Dyspepsia 3 6% 3 6% 3 2% 0 0% 0 0%
Mouth ulcer 3 6% 3 6% 4 2% 0 0% 0 0%
Nausea 24 51% 24 51% 42 22% 0 0% 0 0%
Vomiting 14 30% 14 30% 26 13% 0 0% 0 0%
General disorders
Fatigue 22 47% 18 38% 53 27% 4 9% 4 2%
Fever 4 9% 4 9% 4 2% 0 0% 0 0%
Flu-like Symptoms 6 13% 6 13% 9 5% 0 0% 0 0%
Infections and infestations
Bronchial Infection 4 9% 2 4% 7 4% 2 4% 2 1%
Lung infection 7 15% 4 9% 6 3% 3 6% 3 2%
Rhinitis infective 5 11% 5 11% 6 3% 0 0% 0 0%




16 34% 14 30% 26 13% 2 4% 2 1%
Neutropenia 22 47% 7 15% 37 19% 15 32% 28 14%
Thrombocytopenia 18 38% 10 21% 53 27% 8 17% 20 10%
Metabolism and nutritional disorders
Anorexia 13 48% 13 28% 24 12% 0 0% 0 0%
Hypoalbuminemia 4 9% 4 9% 5 3% 0 0% 0 0%
Hypokalaemia 5 11% 5 11% 5 3% 1 2% 1 1%
Hypophosphatemia 3 6% 3 6% 4 2% 0 0% 0 0%
MSK and connective tissue
Back Pain 3 6% 3 6% 3 2% 0 0% 0 0%
Muscle cramps 3 6% 3 6% 3 2% 0 0% 0 0%
Pain in extremity 4 9% 4 9% 4 2% 0 0% 0 0%
Nervous system disorders
Headache 10 21% 8 17% 12 6% 0 0% 0 0%
Psychiatric disorders
Depression 3 6% 2 4% 2 1% 0 0% 0 0%
Respiratory and thoracic disorders
Cough 3 6% 3 6% 3 2% 0 0% 0 0%
Dyspnoea 4 9% 4 9% 6 3% 0 0% 0 0%
Adverse Events categorised and graded according to CTCAE v 4.03
CTCAE National Cancer Institute Common Terminology for Adverse Events, ECG QTc electrocardiogram corrected QT interval, MSK musculoskeletal, UTI urinary
tract infection
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nausea was reported in 22% of cycles and vomiting in
13%. At the time of the data cut off, 4 patients discontin-
ued treatment for toxicity: 2 because of asymptomatic
QT prolongation during the first cycle, 1 because of
grade 4 fatigue in the 8 cycle and 1 because grade 4
thrombocytopenia during the second cycle, although
simultaneous progression of T-cell lymphoma may have
been a contributing factor in this case. Further to these,
3 patients discontinued because of investigator or patient
decision and a single patient continued treatment, the
remaining 41 stopped treatment for progressive disease.
Efficacy
Best response to CXD101 is shown in Table 3 for subjects
dosed at ≥16mg twice a day (80% of RP2D). There were
no responses in the solid-organ cancer patients, although
as shown in Fig. 1 there were 3 subjects treated for more
than 6 cycles (4months) without progression who derived
clinical benefit (1 carcinoma of the cervix, 1 non-small cell
lung carcinoma, and 1 peritoneal carcinoma): this last sub-
ject continues treatment after 24 cycles.
In the subjects with lymphoma the ORR was 17% with 3
PRs and 1 CR (Table 3). The subject who attained a CR
had follicular lymphoma, the 3 subjects with a PR had
classic Hodgkin lymphoma (2 subjects) and angioimmu-
noblastic T-cell lymphoma (1 subject). The median dur-
ation of response was 6.3 months. A further 4 patients, all
with classic Hodgkin lymphoma, were treated for more
than 4months and derived clinical benefit. As shown in
Fig. 2, a reduction in tumour volume as assessed by the
sum of products of diameters was seen in 6 of the 13 pa-
tients with a best response of stable disease.
Median PFS for the whole cohort was 1.2 months
(95%CI 1.2–2.6), and for the solid organ patients 1.2
months (95%CI 1.2–5.4) and for the lymphoma patients
2.6 months (95%CI 1.2–5.6) Kaplan-Meier plots depicting
the survival functions are shown in Supplementary Fig. 1.
HR23B biomarker analysis
Baseline tumour biopsy samples for HR23B analysis by
immunohistochemistry were available for 43 of the total
47 patients in the study (all the solid-organ cancer pa-
tients required an HR23b result for eligibility in the ex-
pansion phase). HR23B status was assessed in all the
patients with available sample. Results showed good
agreement between pathologists, with exact concordance
in 31 of 44 samples; in the remaining 11 samples there
were only 2 subjects (one diffuse large B-cell lymphoma
(DLBCL) and one T-cell lymphoma) in which the dis-
crepancy was by more than 1 point. Analysis of the dose
escalation cohort has been presented previously [20].
Full HR23B data scoring data are given in Supplemen-
tary Table 2.
In the lymphoma patients treated with ≥16mg twice
daily baseline biopsies were available for 22 of the 23 pa-
tients and there was exact agreement between patholo-
gists in 17 samples; in the remaining samples no
discrepancy was by more than one point, and in no case
was a there a discrepancy between pathologists as to
whether the score was positive or negative.
Responses according to HR23B status are shown in
Table 3. There was no clear correlation between HR23B
status and probability of response. Fifteen of twenty-one
(71%) evaluable subjects with lymphoma baseline
tumour biopsies were positive for HR23B, amongst
whom there was one CR and 1 PR. HR23B positive sta-
tus therefore had a positive predictive value for objective
response of 13% and for stable disease + objective re-
sponse of 53%; and negative predictive value for object-
ive response of 67% and for stable disease + objective
response of 57%.
Discussion
The study achieved the primary objective to investigate
the safety, tolerability and dose limiting toxicity of
CXD101 in patients with advanced malignancies, with a
total of 36 patients treated at ≥80% of the R2PD.
Overall CXD101 was well tolerated, with no deaths on
treatment. The adverse event profile is similar to that re-
ported with other HDAC inhibitors. For example rates
of ≥ grade 3 infection, thrombocytopenia, or, any grade
of vomiting or diarrhoea are similar to data from Phase
Table 3 Best response to CXD101 in patients dosed at CXD101 doses of ≥16 mg twice daily
Response Solid organ, all HR23B
positive N = 11
Lymphoma HR23B
Negative N = 7
Lymphoma HR23B
Positive N = 15
Lymphoma HR23B score
not available N = 1
Lymphoma
total N = 23
All patients
N = 34
NE 2 1 0 0 3 5
PD 5 2 7 1 8 13
SD 4 2 6 0 8 12
PR 0 2 1 0 3 3
CR 0 0 1 0 1 1
ORR 0 29% 13% 0% 17% 12%
Responses shown according to RECIST v 1.1 for solid organ cancers and Cheson 2014 for lymphomas. HR23B status shown according to immunohistochemistry
score on baseline tumour biopsy
NE not evaluable, PD progressive disease, SD stable disease, PR partial response, CR complete response, ORR Overall response rate (PR + CR)
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2 studies of other HDAC inhibitors (vorinostat, romi-
depsin, belinostat, panobinostat): grade ≥ 3 infection 3–
18%, grade ≥ 3 thrombocytopenia 2–26%, grade ≥ 3 an-
aemia 2–18%, any grade of vomiting 24–39% and any
grade of diarrhoea 20–49% [7–9, 13, 25]. The rate of fe-
brile neutropenia was low at 3% of cycles of CXD101.
Clinically significant QT prolongation occurred in 2 pa-
tients. Although it is not possible to draw definite con-
clusions from the number of patients in this study
regarding frequency of adverse events as compared to
other HDAC inhibitors, QTc prolongation does occur
with CXD101 and subsequent studies will provide fur-
ther data to clarify this risk (e.g. NCT03993626). Despite
the theoretical potential for retinal toxicity, this was not
observed in the study.
Samples for baseline HR23B expression were available
in more than 90% of patients. Scoring by IHC was repro-
ducible with good agreement between pathologists. We
did not observe a relationship between HR23B expres-
sion and objective response, or a combination of object-
ive response and stable disease in the patients with
lymphoma. This may have been a consequence of
changes in HR23B expression between the biopsy date
and starting trial treatment, given that the majority of bi-
opsies were archival rather than fresh during screening
and the stability of HR23B over time and with successive
lines of therapy, which vary between patients, is poorly
understood, as is also the case for many potential bio-
markers. The heterogeneity of the lymphoma subtypes
treated and their variation in histological growth pat-
terns may also be a relevant factor and complicating the
interpretation of an immunohistochemical scoring sys-
tem as used in this study. On the basis of the current
data HR23B on archival tissue is therefore not a bio-
marker for response to CXD101 in patients with unse-
lected lymphomas [18]. Moreover, the principal
mechanisms of CXD101 anti-tumour activity may be in-
dependent of HR23B and inhibition of proteasome func-
tion, for example through changes in histone structure
or changes to acetylation states of non-histone proteins
such as the tumour suppressor p53 [26–28]. Activation
of immune mechanisms is also likely to be significant in
Fig. 1 Swimmer plot of treatment duration by CXD101 dose and tumour histology * Recommended Phase 2 dose
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CXD101’s action. In human colorectal cancer cell lines
and murine colorectal cancer models CXD101 treatment
has recently been shown by gene expression profiling to
be associated with increased expression of genes associ-
ated with antigen processing and presentation, such as
major histocompatibility antigen (MHC) class 1 and
class 2 genes, as well as increased expression of genes in-
volved pathways associated with natural killer cell medi-
ated cytotoxicity [29]. An immune mechanism of action
is supported by the finding in this study that lymphocyte
and natural killer cell populations in the tumour micro-
environment are altered by CXD101 and that efficacy of
CXD101 is enhanced when combined with immune
checkpoint inhibitors in murine models.
The lack of objective response in patients with solid
organ malignancies is consistent with other published
studies of HDAC inhibitors and the lack of licensed
agents of this class for solid-organ cancers. Resistance to
HDAC inhibitors as single agents is clearly an significant
issue which remains incompletely understood, proposed
mechanisms including increased expression of the cell
cycle regulators B-cell lymphoma-2 or p21, and constitu-
tive activation of NF-κB [5]. The previously published
pharmacokinetic data demonstrate plasma levels well
within the in vitro biologically active range at the RP2D,
and there was no difference in plasma levels between re-
sponders and non-responders, making it unlikely that an
alternative dose would deliver greater efficacy without
unacceptable toxicity.
We have observed activity of CXD101 in relapsed / re-
fractory lymphoma with an ORR of 17%. Responses were
seen across the principle histological divisions (cHL, and
both B-cell and T-cell NHL), despite a median of 4 prior
lines of therapy. The responses proved reasonably dur-
able at a median of 27 weeks, allowing one patient with
cHL to be bridged directly to allogeneic haematopoietic
stem cell transplant. Another patient with cHL with a
best response of stable disease responded well to their
next line of therapy with a platinum-based salvage
chemotherapy regimen and also successfully underwent
allogeneic-HSCT. The diversity of histologies and doses
analysed treated in this initial Phase I/II study limits
Fig. 2 Best tumour responses in patients with lymphoma evaluable for response. Best tumour responses as assessed by sum of product diameters of
target lesions in evaluable patients with lymphoma (in percentage) for CXD101 doses of ≥16mg twice daily in patients shown according to baseline
tumour HR23B status by immunohistochemistry and best disease response by Cheson et al. [21]. Two patients (1 FL and 1cHL) were not evaluable for
objective response but clinically had a best response of progressive disease. * denotes patients with reduction in target lesions but clear progression of
non-target lesions and / or new lesions. cHL classic Hodgkin lymphoma; GZL grey zone lymphoma; AITL angioimmunoblastic T-cell lymphoma; PTCL
Peripheral T-cell lymphoma NOS; FL follicular lymphoma
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interpretation of this ORR, but to give some context, the
reported ORR with single agent romidepsin or belinostat
in R/R peripheral T-cell lymphoma was 25–26%; with
panobinostat in cHL was 27%, and for vorinostat in fol-
licular lymphoma was 49%.
Several other classes of agent have been proposed as
rational combinations with HDAC inhibitors on the
basis of in vitro data, including drugs targeting DNA re-
pair mechanisms or the DNA damage response, immune
checkpoint inhibitors, proteasome inhibitors and hypo-
methylating agents [5]. Data from several tumour types
indicate HDAC inhibitors increase MHC class I expres-
sion, counteracting the immune evasion undertaken by
many cancers, as well as increasing chemokine expres-
sion and T-cell recruitment to the tumour [29–34]. In
mouse models HDAC inhibitors have been shown to re-
store sensitivity to PD-1 blockade in models of lymph-
oma [35]. CXD101 is currently undergoing evaluation in
combination with nivolumab in patients with metastatic
microsatellite-stable colorectal cancer, including assess-
ment of HR23B alongside MHC I and II and PD-1 ex-
pression as potential biomarkers of response in this
context. (ClinicalTrials.gov identifier: NCT03993626).
Conclusions
CXD101 20mg twice a day for 5 days of a 21 day cycle
was tolerable and showed activity in lymphoma across a
range of subtypes, but objective responses to single agent
CXD101 were not seen in solid organ cancers. Further
evaluation of the activity of CXD101 in specific tumour
populations and in combination with checkpoint inhibi-
tors, or potentially other agents, is warranted in order to
better understand its optimal use and potential bio-
markers of response.
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